الفهرس 
Gastroretentive system for delivering an antipsychotic drug
ContentsOnly 14 pages are availabe for public view
 |  | from | 288 |  |  |
| | | from | 288 | | |
Abstract
Schizophrenia is a severe and disabling mental illness. It affects approximately 1% of the population worldwide and it is a chronic, severe disorder, lacking curative treatment. The suicide rate is as high as 9 - 13%, with the incidence of suicide attempt reaching 50% of diagnosed patients over a lifetime. The onset of schizophrenia usually occurs around 18 - 25 years of age and is often preceded by premorbid behavioural deviations, such as social withdrawal and affective changes. The symptoms and severity can vary over individual with schizophrenia. The symptoms are commonly divided into three categories, namely, positive symptoms, negative symptoms and cognitive deficits. Antipsychotics can be broadly classified into first generation antipsychotics (FGAs, formerly known as {u2018}typical{u2019} antipsychotics) and second generation antipsychotics (SGAs, formerly known as {u2018}atypical{u2019} antipsychotics). First - generation antipsychotics are as effective as second - generation drugs in treating the 2positive3 symptoms of schizophrenia, such as hallucinations, delusions, and paranoia, although they vary in their propensity to cause side effects